Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Belgo-Dutch clinical-stage biotech argenx saw its shares close up nearly 30% at $190.00 on Tuesday, after it released top-line trial results for its myasthenia gravis drug candidate. 27 May 2020
Biotechnology
US pharma major Merck & Co has not previously been the noisiest of drug companies when talking about its work in COVID-19, but it now appears to be making up for this. 27 May 2020
Biotechnology
The US Food and Drug Administration has approved a label extension for Dupixent (dupilumab), to include treatment of children aged six to 11 with moderate-to-severe atopic dermatitis (AD). 27 May 2020
Biotechnology
Privately-owned Austrian biotech Themis Bioscience and MSD (the trading name used by US pharma giant Merck & Co outside North America) have entered into a definitive agreement under which MSD will acquire Themis. 26 May 2020
Biotechnology
Genomic analysis company ArcherDx has announced a strategic collaboration with AstraZeneca to develop assays to support multiple planned Phase III trials for the pharma major’s targeted immuno-oncology therapeutics. 26 May 2020
Biotechnology
US biotech Novavax saw its share price jump by 14% in Tuesday morning’s trading as it became the latest company to announce that trials of its coronavirus vaccine have begun. 26 May 2020
Biotechnology
French pharma major Sanofi has announced its intent to sell its equity investment in US biotech company Regeneron. 26 May 2020
Biotechnology
Japanese drugmaker Shionogi said today that, at a meeting of the board of directors held on May 25, it was resolved to take up an option to acquire all the shares of US biotech firm Tetra Therapeutics. 26 May 2020
Biotechnology
Less than two year after engaging a new head of the company, Stockholm, Sweden-based biotech Medivir has appointed a new chief executive, namely Yilmaz Mahshid. 26 May 2020
Biotechnology
Canada-based BetterLife Pharma yesterday announced that it has secured "hard" lock-up agreements from shareholders of Altum Pharmaceuticals representing 67.12% of the outstanding common shares of the Canadian biotech. 26 May 2020
Biotechnology
Study results released on Friday of 108 adults has found that Chinese biotech firm CanSino Biologic’s vaccine Ad5-nCoV produced neutralizing antibodies and T-cell response against SARS-CoV-2, but further research is needed to confirm whether the vaccine protects against SARS-COV-2 infection. 25 May 2020
Biotechnology
Sino-America immuno-oncology biotech firm BeiGene has entered into an exclusive distribution agreement with Israel’s Medison Pharma to commercialize its BTK inhibitor Brukinsa (zanubrutinib) in Israel and the acceptance of a new drug application (NDA) in Israel for Brukinsa for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. 25 May 2020
Biotechnology
Accelerated FDA approval for Alunbrig in first-line setting for rare and serious form of lung cancer
The US Food and Drug Administration has approved Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. 23 May 2020
Biotechnology
A week after the US Food and Drug Administration (FDA) refused to review idecabtagene vicleucel (ide-cel; bb2121), the European Medicines Agency (EMA) has accepted a filing for the CAR-T therapy. 23 May 2020
Biotechnology
Reversing a previous negative decision, the UK’s reimbursement agency has provided final guidance in favor of immunotherapy Tecentriq (atezolizumab), plus chemo, for triple negative breast cancer. 22 May 2020
Biotechnology
UK biotech Tiziana Life Sciences today said it intends to demerge its StemPrintER and SPARE (togetherStemPrintER) genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity. 22 May 2020
Biotechnology
US clinical-stage drug developer Synlogic’s shares plummeted 25.5% to %1.81 in pre-market trading Thursday after it revealed that its collaboration with AbbVie for the development of Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD) had been terminated. 22 May 2020
Biotechnology
Roche data from two pivotal Phase III open-label extension studies shows satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in neuromyelitis optica spectrum disorder (NMOSD). 22 May 2020
Biotechnology
A new partnership between South Korea’s Samsung Biologics and UK-based GlaxoSmithKline will ensure additional capacity for the manufacture and supply of GSK's novel biologics. 22 May 2020
Biotechnology
In a move aimed at boosting development of its nanopore sequencing technology, Swiss cancer giant Roche has bought out early-stage sequencing expert Stratos Genomics. 22 May 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze